Recombinant CTLA-4 (Ipilimumab Biosimilar) anticorps

N° du produit ABIN7200671

Cet anticorps Souris Monoclonal détecte spécifiquement CTLA-4 (Ipilimumab Biosimilar) dans FACS et in vivo. Il présente une réactivité envers Humain.

Aperçu rapide pour Recombinant CTLA-4 (Ipilimumab Biosimilar) anticorps (ABIN7200671)

Antigène: CTLA-4 (Ipilimumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CTLA-4 (Ipilimumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Détail du produit anti-CTLA-4 (Ipilimumab Biosimilar) anticorps

Fonction: Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody

Specificité: The in vivo grade ipilimumab biosimilar specifically binds to the human CTLA4.

Attributs du produit: Recombinant fully human IgG1 monoclonal antibody.

Purification: Protein A affinity column

Pureté: > 95% by SDS-PAGE under reducing conditions and HPLC.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method.

Immunogène: The anti-human CTLA-4 monoclonal antibody ipilimumab biosimilar was produced in the ipilimumab biosimilar CHO stable cell line.

Isotype: IgG1 kappa

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ipilimumab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur CTLA-4 (Ipilimumab Biosimilar)

Antigène: CTLA-4 (Ipilimumab Biosimilar)

Classe de substances: Biosimilar

Sujet: What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.